Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis
Main finding · Incident diabetesResult — go to the resultHazard ratio 0.84 95% CI 0.78–0.90Authors' conclusion
The results from this cohort study indicating that denosumab treatment was associated with lower risk of incident diabetes
Study context
- Population
- Adults who received denosumab for osteoporosis in Taiwan, 2012–2019 (National Health Insurance Research Database); mean age 77.7 years, 84.3% femaleafter propensity score matching
- Participants
- 68,510 adults
- Exposure
- Denosumab initiated and adhered to vs denosumab discontinued after the initial dose
- Treatmentn = 34,255
- Comparisonn = 34,255reference
- Outcome
- Incident diabetes requiring treatment with antidiabetic drugs
Methodological detailsnationwide, propensity score-matched, Cox proportional hazards model
- Nationwide
- Propensity score-matched
- Cox proportional hazards model
Main finding
Incident diabetes · mean follow-up 1.9 (SD 1.6) years
Hazard ratio
0.84
95% CI 0.78–0.90
Events by group
Treatmentvs Comparison
HR 0.84 (95% CI 0.78–0.90)
As reported in the abstract
Observational data: associations, not effects.
Further findings
- Several sensitivity analyses also demonstrated similar results of lower diabetes risk associated with denosumab treatment
Original publication
Denosumab and the Risk of Diabetes in Patients Treated for Osteoporosis. JAMA Netw Open. Published 5 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →